Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

WEBINAR: Assessing Immunotherapy Toxicity in NHPs

November 20, 10am and 10pm EST

Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

WEBINAR: Applications of HUB Tumor Organoids in Oncology Drug Discovery

Wednesday November 13, 2019 - 4am/10am/5pm ET

Presented by Dr Rajendra Kumari this webinar will discuss the drug discovery applications of HUB tumor organoids including large scale drug screening, in vivo model selection, and in silico drug discovery. She'll also explore how to improve predictivity in drug development with our unique matched in vitro PDXO/in vivo PDX pairs.

Download Our 9 AACR-NCI-EORTC Posters

Review our latest oncology and immuno-oncology posters including tumor organoids for drug discovery and I/O drug development, orthotopic syngeneic models, and immunoprofiling data.

NEW WHITE PAPER! HUB Organoid Technology: Advantages in 3D In Vitro Modeling

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

ON DEMAND WEBINAR: How to Detect, Characterize, and Evaluate CAR-T Cell Therapies

Presented by Dr Rajendra Kumari this webinar explores how to overcome translational challenges in CAR-T cell therapy development. Learn more on the different preclinical models available for CAR-T and cell therapy efficacy and safety assessment including PDX, as well as a novel rare cell analysis platform for sensitive CAR-T detection.

ON DEMAND WEBINAR: Preclinical Obesity Research: Best Practice in Model Selection and Study Design

Presented by Dr Fred Beasley this webinar explores how to select the most appropriate models for your preclinical obesity studies, including polygenic vs monogenic models and recommendations based on drug modes of action. We also review best practice in obesity study design to maximize data outcomes.

ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

NEW WHITE PAPER: How to Assess Immunotherapy Toxicity using NHPs

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

November 5, 2019

Cancer Biomarkers: Improving Detection and Treatment

Explore the three main types of cancer biomarkers and their main uses in cancer diagnosis, informing prognosis, and guiding treatment decisions. Review the vast array of biomolecules which act as cancer biomarkers, including genetic, transcriptomic, epigenetic, proteomic, and metabolomic biomarkers.

Read More

November 5, 2019

Cancer Biomarkers: Improving Detection and Treatment

Explore the three main types of cancer biomarkers and their main uses in cancer diagnosis,...

Read More

October 30, 2019

The Biological Equivalence of PDXs and PDXOs

Learn about patient-derived xenograft (PDX) and PDX-derived organoid (PDXO) biological...

Read More

October 29, 2019

Advances in In Vivo Oncology Models at AACR-NCI-EORTC 2019

In Boston this week we’re presenting all the latest updates across our panels of in vivo...

Read More

October 28, 2019

New Organoid Platforms for Oncology and I/O Drug Discovery at AACR-NCI-EORTC 2019

2019 has been an exciting year at CrownBio with the addition of organoid platforms to our...

Read More

October 28, 2019

Biomarker Discovery and MOA Evaluation through Genomic and Proteomic Profiling at AACR-NCI-EORTC 2019

This week in Boston we’re presenting data on our new analysis platform and preclinical...

Read More

Upcoming Events


November 20, 2019

Webinar: Assessing Immunotherapy Toxicity in NHPs


November 28-29, 2019

UK Translational Oncology Seminar Series

Oxford, Cambridge UK


December 4-6, 2019

8th Annual PREDiCT: Tumor Models London Summit

London, UK


December 11-14, 2019

ESMO Immuno-Oncology Congress 2019

Geneva, Switzerland